Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
Nanjing General Hospital of Nanjing Military Command · Jinling Institute of Technology · +18 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
637
total citations
- FWCI
- 50.89
- Percentile
- 100%
- References
- 31
Citations per year
Authors
16- SQShukui QinCorresponding
Nanjing General Hospital of Nanjing Military Command, Jinling Institute of Technology
- ZRZhenggang Ren
Fudan University, Zhongshan Hospital
- ZMZhiqiang Meng
Fudan University Shanghai Cancer Center
- ZCZhendong Chen
Anhui Medical University, Second Affiliated Hospital of Anhui Medical University
- XCXiaoli Chai
Hunan Cancer Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Hepatocellular carcinoma
- Internal medicine
- Clinical endpoint
- Randomized controlled trial
- Adverse effect
- Sorafenib
- Clinical trial
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.